Cargando…
Audit of data redaction practices in NICE technology appraisals from 1999 to 2019
OBJECTIVES: To assess the extent and type of data redaction in all active technology appraisals (TA) and highly specialised technology (HST) evaluations issued by the National Institute for Health and Care Excellence (NICE) from its conception of the institute to September 2019. To propose policy re...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496400/ https://www.ncbi.nlm.nih.gov/pubmed/34615680 http://dx.doi.org/10.1136/bmjopen-2021-051812 |
_version_ | 1784579750405079040 |
---|---|
author | Osipenko, Leeza |
author_facet | Osipenko, Leeza |
author_sort | Osipenko, Leeza |
collection | PubMed |
description | OBJECTIVES: To assess the extent and type of data redaction in all active technology appraisals (TA) and highly specialised technology (HST) evaluations issued by the National Institute for Health and Care Excellence (NICE) from its conception of the institute to September 2019. To propose policy recommendations for transparency. METHODS: Structured audit to establish extent of data redaction—proportion of appraisals and specific data categories and assess redaction by: indication, appraisal process, manufacturer, type of data—price, adverse events (AEs), clinical (excluding AEs), incremental quality-adjusted life-years. Longitudinal analysis over 20 years. RESULTS: All TAs with available documentation and active recommendations (n=408) and HSTs (n=10) published from March 2000 to 11 September 2019 have been assessed for data redaction. Overall, 333 TAs (81.6%) have data redaction, 86 (25.8%) of them are heavily redacted. Clinical data (excluding AEs) are redacted in 268 (65.7%) appraisals, AE data in 128 (31.4%), price in 238 (58.3%). In total, 87% of oncology appraisals have redacted data vs 78% of non-oncology appraisals. 91% of single TAs have redacted data vs 59% of multiple TAs. 25% of final guidance documents (e.g. Final Appraisal Determination - FAD) do not report one or more instance of clinical data. Data redaction increased substantially over time, and is currently at its highest level with 100% of TAs having at least some data redaction in 2019/2020, 96% of appraisals in 2018/2019% and 94% of appraisals in 2017/2018. All 10 HST evaluations have redacted data, with 4 of them being heavily redacted. CONCLUSIONS: Documents supporting NICE TA and HST recommendations are significantly redacted, thereby concealing clinical and economic data of importance to patients, clinicians and researchers. Documents remain redacted on the NICE website for years. Policy change is required to ensure transparency of data underpinning NICE’s decisions. |
format | Online Article Text |
id | pubmed-8496400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-84964002021-10-22 Audit of data redaction practices in NICE technology appraisals from 1999 to 2019 Osipenko, Leeza BMJ Open Health Policy OBJECTIVES: To assess the extent and type of data redaction in all active technology appraisals (TA) and highly specialised technology (HST) evaluations issued by the National Institute for Health and Care Excellence (NICE) from its conception of the institute to September 2019. To propose policy recommendations for transparency. METHODS: Structured audit to establish extent of data redaction—proportion of appraisals and specific data categories and assess redaction by: indication, appraisal process, manufacturer, type of data—price, adverse events (AEs), clinical (excluding AEs), incremental quality-adjusted life-years. Longitudinal analysis over 20 years. RESULTS: All TAs with available documentation and active recommendations (n=408) and HSTs (n=10) published from March 2000 to 11 September 2019 have been assessed for data redaction. Overall, 333 TAs (81.6%) have data redaction, 86 (25.8%) of them are heavily redacted. Clinical data (excluding AEs) are redacted in 268 (65.7%) appraisals, AE data in 128 (31.4%), price in 238 (58.3%). In total, 87% of oncology appraisals have redacted data vs 78% of non-oncology appraisals. 91% of single TAs have redacted data vs 59% of multiple TAs. 25% of final guidance documents (e.g. Final Appraisal Determination - FAD) do not report one or more instance of clinical data. Data redaction increased substantially over time, and is currently at its highest level with 100% of TAs having at least some data redaction in 2019/2020, 96% of appraisals in 2018/2019% and 94% of appraisals in 2017/2018. All 10 HST evaluations have redacted data, with 4 of them being heavily redacted. CONCLUSIONS: Documents supporting NICE TA and HST recommendations are significantly redacted, thereby concealing clinical and economic data of importance to patients, clinicians and researchers. Documents remain redacted on the NICE website for years. Policy change is required to ensure transparency of data underpinning NICE’s decisions. BMJ Publishing Group 2021-10-06 /pmc/articles/PMC8496400/ /pubmed/34615680 http://dx.doi.org/10.1136/bmjopen-2021-051812 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Health Policy Osipenko, Leeza Audit of data redaction practices in NICE technology appraisals from 1999 to 2019 |
title | Audit of data redaction practices in NICE technology appraisals from 1999 to 2019 |
title_full | Audit of data redaction practices in NICE technology appraisals from 1999 to 2019 |
title_fullStr | Audit of data redaction practices in NICE technology appraisals from 1999 to 2019 |
title_full_unstemmed | Audit of data redaction practices in NICE technology appraisals from 1999 to 2019 |
title_short | Audit of data redaction practices in NICE technology appraisals from 1999 to 2019 |
title_sort | audit of data redaction practices in nice technology appraisals from 1999 to 2019 |
topic | Health Policy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496400/ https://www.ncbi.nlm.nih.gov/pubmed/34615680 http://dx.doi.org/10.1136/bmjopen-2021-051812 |
work_keys_str_mv | AT osipenkoleeza auditofdataredactionpracticesinnicetechnologyappraisalsfrom1999to2019 |